<DOC>
	<DOC>NCT01824238</DOC>
	<brief_summary>This study will evaluate the effects of anacetrapib (MK-0859) on low-density lipoprotein-cholesterol (LDL-C) when compared to placebo in Japanese participants with heterozygous familial hypercholesterolemia when added to an existing statin lipid-modifying therapy.</brief_summary>
	<brief_title>A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Anacetrapib</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>If female, cannot be of reproductive potential Diagnosed with heterozygous familial hypercholesterolemia Have been treated with an appropriate and stable dose of statinÂ± other lipidlowering medication(s) for at least 6 weeks Previously participated in a study with a cholesteryl ester transfer protein (CETP) inhibitor Homozygous familial hypercholesterolemia Severe chronic heart failure Uncontrolled cardiac arrhythmias, myocardial infarction (MI), percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), unstable angina, or stroke within 3 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>